OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Research Partnership's new report on living with rheumatoid arthritis (RA) is aimed at "helping pharmaceutical companies understand the attitudes and unmet needs of people with RA and how current market dynamics, with the advent of new biologics/biosimilars and oral JAK inhibitors, have affected patients’ views and behaviours towards their RA". Living with Rheumatoid Arthritis (RA) is based on 431 patients diagnosed with RA in the 5 EU markets (France, Germany, Italy, Spain, UK), 56 patients in Japan, and 112 patients in Canada. The study consists of 30-minute quantitative online and qualitative telephone interviews with patients. Research Partnership's Mariel Metcalfe commented: “An inescapable characteristic of RA is that it is unpredictable and can highly impact patients’ practical and emotional lives. While the range of RA treatments has grown, it is even more important to understand and measure how patients view these treatments and if they are truly meeting their needs.” Living with RA is one in a series of "Living With" reports offering insight into the chronic disease patient journey from pre-diagnosis to stabilization, which include Atopic Dermatitis (EU & US), Psoriasis (EU), NASH (EU & US) and Diabetes LATAM. www.researchpartnership.com/livingwith